We are a clinical stage biotechnology company focused on the development of novel therapeutics and diagnostics in oncology, neurology, and rare pediatric diseases, medical countermeasures, and viral disease.


Our vision is to deliver promising, transformative science to underserved patients. Our name symbolizes our mission to partner with clinicians and scientists to help people who are in urgent need.



Advancing novel therapeutics and radioimaging agents with standards of excellence in several degenerative disease areas.
Our world class research 
drives life-changing innovation for patients in oncology, neurology, and
rare pediatric diseases.
Collaborate with us to leverage our technologies and expertise to discover, develop, and deliver ground-breaking results to patients.

4.8 years

average wait from first symptom to diagnosis

for rare pediatric disease[1]

Our innovations in drug development help families to find a clearer pathway to diagnosis of children's rare diseases. That's impactful; and it's what drives us every day at AIP. 

Roseanne Satz, Chief Executive Officer and Founder

Our team has deep knowledge in radiation physics, leading to advances in the use of Positron Emission Tomography and Peptide Receptor Radionuclide Therapy.

If you have a question and would like
to contact us, please reach out.